After Oppenheimer and H.C. Wainwright gave Achieve Life Sciences (NASDAQ: ACHV) a Buy rating last month, the company received another Buy, this time from Maxim Group. Analyst Jason McCarthy initiated coverage with a Buy rating on Achieve Life Sciences yesterday and set a price target of $21.00. The company’s shares closed last Friday at $6.64.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -39.8% and a 9.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.
Achieve Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $26.67, which is a 315.2% upside from current levels. In a report issued on April 28, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $50.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $10.40 and a one-year low of $5.62. Currently, Achieve Life Sciences has an average volume of 88.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products, cytisine, is a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Read More on ACHV:
- Veru (VERU) Gets a Buy Rating from Brookline Capital Markets
- Lineage Cell Therapeutics (LCTX) Received its Third Buy in a Row
- Maxim Group Thinks Citius Pharmaceuticals’ Stock is Going to Recover
- Maxim Group Initiates a Buy Rating on Panbela Therapeutics (PBLA)
- Wendy’s (WEN) Gets a Buy Rating from J.P. Morgan
